Enigmatic lessons from dermatologists:pharmaco-oncogenesis and nitrosogenesis of skin cancer: facts and controversies
Medical Review (Med. pregled), 2024, 60(3), 67-72.
G.Tchernev1,2, N. Naydekova2, L. Ivanov2, S. Kordeva1, A. C. Simon1
1 Onkoderma – Clinic for Dermatology, Venereology and Dermatologic Surgery
2 Department of Dermatology and Venereology, Medical Institute of Ministry of Interior – Sofia
Abstract. The contribution of dermatologists to global oncology also remains largely attributable to the incidental identification or clinicopathologic correlations between the intake of nitrosamine-contaminated drugs and the subsequent generation of melanomas and keratinocytic cancers. The slow and gradual identification of an increasing number of nitrosamine containing drugs, and their subsequent associ-ation with the development of heterogeneous forms of skin cancer, underlies the newly introduced concept, now also known as drug-induced nitrosogenesis/carcinogenesis or that of skin cancer pharmaco-oncogenesis. Of undoubted interest is also the fact that the intake of mono- or polycontaminated drugs in the context of polymorbidity could (according to recent analyzes) also be controlled and not only be sporadic or unexplained. It is this that necessitates, albeit to some extent according to some, the speculative claim that cancer could be controlled and ni-trosamines are genetic weapon for controlled cancer causation. The resolution of this dilemma could be accomplished through several non-negligible steps such as 1) accurate cataloguing of nitrosamines or their derivatives on each and every drug package – in terms of availability and concentration, 2) certificates of drug purity on each batch, 3) independent additional monitoring of nitroso incidence once the certificates are formalized, 4) an official online database for cataloguing the side effects of nitroso-contaminated drugs (accessible and transparent to end-users, manufactured; or 5) complete elimination of nitroso components from medicinal preparations. Oncopharmacogenesis/pharmaco-oncogenesis of skin cancer is a concept that is key, enigmatic and without analogue. It should not be confused with concepts such as pharmacogenetics/ pharmacogenomics. The reason this concept (onco-pharmacogenesis/pharmaco-oncogenesis) came up was defined by the FDA and its enigmatic revelations of nitrosocontamination (cancer related nitrosogenesis) of drug production back in 2018.
Key words: Nitrosogenesis, skin cancer, melanoma, polycontamination, NDSRIs, nitrosamines
Address for correspondence: Prof. Georgi Tchernev, MD, e-mail: georgi_tchernev@yahoo.de, рhone: +359 885 588 424